Streetbeat News

Revenues

FOSL

Fossil Group projects its worldwide net sales to reach approximately $1.2 billion for the fiscal year 2024.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:09 pm

ECOR

electroCore (NASDAQ:ECOR) reported Q4 2023 GAAP EPS of $(0.61), meeting analyst consensus estimates, with sales of $5.191M surpassing the $4.967M estimate, marking a 102.77% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:07 pm

HOOD

Robinhood Markets reported net deposits of $3.6 billion in February, indicating a significant level of user engagement and capital inflow.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:07 pm

VRM

Vroom (NASDAQ:VRM) reported Q4 sales of $235.92M, surpassing the analyst consensus estimate of $232.00M by 1.69% and marking a 12.69% increase from the same period last year.

Portfolio Pulse from Happy Mohamed

March 13, 2024 | 8:06 pm

SLN

Four analysts have recently updated their ratings on Silence Therapeutics (NASDAQ:SLN), with a mix of bullish and somewhat bullish perspectives. The average 12-month price target is now $73.00, down from $75.00, with a high estimate of $75.00 and a low of $67.00. Silence Therapeutics, a biotech company, is working on therapies SLN360 and SLN124 for heart disease and anemia, respectively. Despite a strong net margin, the company has seen a revenue decline of -17.0% and has below-average ROE and impressive ROA.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:01 pm

JPM

Analysts have diverse views on JPMorgan Chase (NYSE:JPM), with recent ratings ranging from bullish to bearish. The average 12-month price target for JPM has increased to $207.0, up 6.94% from $193.56. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their reaction to JPMorgan Chase's performance and market conditions. JPMorgan Chase, a major financial institution with nearly $4 trillion in assets, has shown significant revenue growth and financial strength, with a notable ROE and ROA.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:01 pm

NBIX

Neurocrine Biosciences (NASDAQ:NBIX) received diverse analyst ratings over the last three months, with an updated average 12-month price target of $151.88, marking a 7.72% increase from the previous target. Analysts from firms like Oppenheimer, JP Morgan, and Citigroup adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Neurocrine Biosciences, a pharmaceutical company, shows a positive revenue trend with a 25.05% growth rate as of December 31, 2023, but faces challenges in profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:00 pm

KSS

Seven analysts have recently updated their ratings on Kohl's (NYSE:KSS), with a mix of views ranging from bullish to bearish. The average 12-month price target for KSS is now $25.29, up from $23.40, with targets ranging from $20.00 to $31.00. Analyst actions include both upgrades and maintains, reflecting varied expectations for the company's performance. Kohl's financials show a challenging revenue trend with a -5.21% growth over 3 months, yet it maintains strong profitability indicators such as a net margin of 1.46% and an ROE of 1.58%. The company's debt management is considered prudent with a debt-to-equity ratio of 2.15.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 6:01 pm

ON

Recent analyst ratings for ON Semiconductor (NASDAQ:ON) show diverse outlooks, with a mix of bullish, somewhat bullish, and indifferent stances. The average 12-month price target is $88.33, slightly up from the previous $88.17. Analyst actions include maintaining, lowering, and raising ratings and price targets, reflecting dynamic market conditions and company performance. ON Semiconductor, a leading supplier in the automotive and industrial markets, faces revenue challenges with a -4.06% decline over 3 months but demonstrates strong profitability and financial health with high net margin and ROE.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 6:01 pm

ATER

Aterian shares are trading lower following the announcement of their Q4 financial results, which were below expectations. Additionally, the company's Q1 net revenue guidance was issued below estimates, further impacting the stock's performance.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 5:56 pm